Design, Synthesis, Molecular Modeling Studies and Biological Evaluation of N'-Arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide Derivatives as Novel Anti-HCV Agents

Document Type : Research article

Authors

1 Department of Pharmaceutical Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Department of Medical Lab Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Medicinal Chemistry, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Abstract

HCV-induced hepatitis is one of the most debilitating diseases. The limited number of anti-HCV drugs and drug-resistance necessitate developing of new scaffolds with different mode of actions. HCV non-structural protein 5B (NS5B) is an attractive target for development of novel inhibitors of HCV replication. In this paper, new N'-arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide derivatives were designed based on the pharmacophores of HCV NS5B active site binding inhibitors. Designed compounds were synthesized and evaluated for their inhibitory activities in a cell-based HCV replicon system assay. Among tested compounds, compounds 18 and 20 were found to be the most active (EC50 = 35 and 70 M, respectively) with good selectivity index (SI > 2) in the corresponding series. Molecular modeling studies showed that the designed compounds are capable of forming key coordination with the two magnesium ions as well as interactions with other key residues at the active site of HCV NS5B.

Keywords

Main Subjects


References
Modi AA and Liang TJ. Hepatitis C: a clinical review.
Oral Dis. (2008) 14: 10-4.
World Health organization, Hepatitis C http://www.
who.int/news-room/factsheets/detail/hepatitis-c
(Accessed on 28th October 2018).
Neukam K, Macías J, Mira JA and Pineda JA. A
review of current anti-HCV treatment regimens and
possible future strategies. Expert Opin. Pharmacother.
(2009) 10: 417-33.
Alexopoulou A and Karayiannis P. Interferon-based
combination treatment for chronic hepatitis C in the
era of direct acting antivirals. Ann. Gastroenterol.
(2015) 28: 55-65.
Lim TR, Tan BH and Mutimer DJ. Evolution and
emergence of a new era of antiviral treatment for
chronic hepatitis C infection. Int. J. Antimicrob.
Agents. (2014) 43: 17-25.
Zajac M, Muszalska I, Sobczak A, Dadej A, Tomczak
S and Jelinska A. Hepatitis C - New drugs and
treatment prospects. Eur. J. Med. Chem. (2019) 165:
225-49.
Asselah T and Marcellin P. Direct acting antivirals for
the treatment of chronic hepatitis C: one pill a day for
tomorrow. Liver Int. (2012) 32: 88-102.
Schinazi R, Halfon P, Marcellin P and Asselah T. HCV
direct-acting antiviral agents: the best interferon-free
combinations. Liver Int. (2014) 34: 69-78.
Gerber L, Welzel TM and Zeuzem S. New therapeutic
strategies in HCV: polymerase inhibitors. Liver Int.
(2013) 33: 85-92.
Shih IH, Vliegen I, Peng B, Yang H, Hebner C,
Paeshuyse J, Purstinger G, Fenaux M, Tian Y, Mabery
E, Qi X, Bahador G, Paulson M, Lehman LS, Bondy
S, Tse W, Reiser H, Lee WA, Schmitz U, Neyts
J and Zhong W. Mechanistic characterization of
GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor
of hepatitis C virus NS5B polymerase. Antimicrob.
Agents Chemother. (2011) 55: 4196-203.
Bressanelli S, Tomei L, Rey FA and De Francesco
R. Structural analysis of the hepatitis C virus RNA
polymerase in complex with ribonucleotides. J. Virol.
(2002) 76: 3482-92.
Appleby TC, Perry JK, Murakami E, Barauskas O,
Feng J, Cho A, Fox D, Wetmore DR, McGrath ME
and Ray AS. Structural basis for RNA replication by
the hepatitis C virus polymerase. Science (2015) 347:
771-5.
Beaulieu P and Tsantrizos Y. Inhibitors of the HCV
NS5B polymerase: new hope for the treatment of
hepatitis C infections. Curr. Opin. Investig. Drugs
(2004) 5: 838-50.
Boyce SE, Tirunagari N, Niedziela-Majka A, Perry
J, Wong M, Kan E, Lagpacan L, Barauskas O, Hung
M and Fenaux M. Structural and regulatory elements
of HCV NS5B polymerase–β-loop and C-terminal
tail–are required for activity of allosteric thumb site II
inhibitors. PLoS One (2014) 9: e84808.
Powdrill MH, Bernatchez JA and Götte M. Inhibitors of
the hepatitis C virus RNA-dependent RNA polymerase
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E
and La Vecchia C. Worldwide mortality from cirrhosis:
An update to 2002. J. Hepatol. (2007) 46: 827-39.
(1)
N′-arylidene-6-(benzyloxy)-4-oxo-1,4-dihydroquinoline-3-carbohydrazide derivatives as novel anti-HCV agents
1801
NS5B. Viruses (2010) 2: 2169-95.
Hajimahdi Z and Zarghi A. Progress in HIV-1 integrase
inhibitors: A review of their chemical structure
diversity. Iran. J. Pharm. Res. (2016) 15: 595.
Summa V, Petrocchi A, Matassa VG, Taliani M, Laufer
R, De Francesco R, Altamura S and Pace P. HCV
NS5b RNA-dependent RNA polymerase inhibitors:
from α,γ-diketoacids to 4,5-dihydroxypyrimidine-or
3-methyl-5-hydroxypyrimidinonecarboxylic acids.
Design and synthesis. J. Med. Chem. (2004) 47:
5336-9.
Koch U, Attenni B, Malancona S, Colarusso S,
Conte I, Di Filippo M, Harper S, Pacini B, Giomini
C, Thomas S, Incitti I, Tomei L, De Francesco R,
Altamura S, Matassa VG and Narjes F. 2-(2-Thienyl)-
5,6-dihydroxy-4-carboxypyrimidines as Inhibitors of
the Hepatitis C Virus NS5B Polymerase:  Discovery,
SAR, Modeling, and Mutagenesis. J. Med. Chem.
(2006) 49: 1693-705.
Chen YL, Tang J, Kesler MJ, Sham YY, Vince R,
Geraghty RJ and Wang Z. The design, synthesis
and biological evaluations of C-6 or C-7 substituted
2-hydroxyisoquinoline-1,3-diones as inhibitors of
hepatitis C virus. Bioorg. Med. Chem. (2012) 20:
467-79.
Kumar DV, Rai R, Brameld KA, Somoza JR,
Rajagopalan R, Janc JW, Xia YM, Ton TL, Shaghafi
MB and Hu H. Quinolones as HCV NS5B polymerase
inhibitors. Bioorg. Med. Chem. Lett. (2011) 21: 82-7.
Chen Y-L, Zacharias J, Vince R, Geraghty RJ and Wang
Z. C-6 aryl substituted 4-quinolone-3-carboxylic acids
as inhibitors of hepatitis C virus. Bioorg. Med. Chem.
(2012) 20: 4790-800.
Cheng Y, Shen J, Peng RZ, Wang GF, Zuo JP and Long
YQ. Structure-based optimization and derivatization
of 2-substituted quinolone-based non-nucleoside HCV
NS5B inhibitors with submicromolar cellular replicon
potency. Bioorg. Med. Chem. Lett. (2016) 26: 2900-6.
Daneshtalab M and Ahmed A. Nonclassical biological
activities of quinolone derivatives. J. Pharm. Pharm.
Sci. (2011) 15: 52-72.
Hajimahdi Z, Ranjbar A, Suratgar AA and Zarghi
A. QSAR Study on anti-HIV-1 activity of 4-oxo1,4-dihydroquinoline and 4-oxo-4H-pyrido[1,2-a]
pyrimidine derivatives using SW-MLR, artificial
neural network and filtering methods. Iran. J. Pharm.
Res. (2015) 14 (Supplement): 69-75.
Hajimahdi Z, Zabihollahi R, Aghasadeghi MR, Ashtiani
SH and Zarghi A. Novel quinolone-3-carboxylic acid
derivatives as anti-HIV-1 agents: design, synthesis,
and biological activities. Med. Chem. Res. (2016) 25:
1861–76.
Hajimahdi Z, Zabihollahi R, Aghasadeghi MR and
Zarghi A. Design, synthesis and docking studies of
new 4-hydroxyquinoline-3-carbohydrazide derivatives
as anti-HIV-1 agents. Drug Res. (2013) 63: 192–7.
Hajimahdi Z, Zarghi A, Zabihollahi R and Aghasadeghi
MR. Synthesis, biological evaluation, and molecular
modeling studies of new 1,3,4-oxadiazole- and
1,3,4-thiadiazole-substituted 4-oxo-4H-pyrido[1,2-a]
pyrimidines as anti-HIV-1 agents. Med. Chem. Res.
(2013) 22: 2467–75.
Parizadeh N, Alipour E, Soleymani S, Zabihollahi R,
Aghasadeghi MR, Hajimahdi Z and Zarghi A. Synthesis
of novel 3-(5-(alkyl/arylthio)-1,3,4-oxadiazol-2-yl)-
8-phenylquinolin-4(1H)-one derivatives as anti-HIV
agents. Phosphorus Sulfur Silicon Relat. Elem. (2018)
193: 225-31.
Faghihi K, Safakish M, Zebardast T, Hajimahdi Z and
Zarghi A. Molecular Docking and QSAR Study of
2-Benzoxazolinone, Quinazoline and Diazocoumarin
Derivatives as Anti-HIV-1 Agents. Iran. J. Pharm.
Res. (2019) 18: 1253-63.
Safakish M, Hajimahdi Z, Zabihollahi R, Aghasadeghi
MR, Vahabpour R and Zarghi A. Design, synthesis,
and docking studies of new 2-benzoxazolinone
derivatives as anti-HIV-1 agent. Med. Chem. Res.
(2017) 26: 2718–26.
Livani ZA, Safakish M, Hajimahdi Z, Soleymani
S, Zabihollahi R, Aghasadeghi MR, Alipour E and
Zarghi A. Design, synthesis, molecular modeling, in
silico ADME studies and anti-HIV-1 assay of new
diazocoumarin derivatives. Iran. J. Pharm. Res.
(2018) 17: 65-77.
Hajimahdi Z, Zabihollahi R, Aghasadeghi MR
and Zarghi A. Design, Synthesis, Docking Studies
and Biological Activities Novel 2,3- Diaryl-4-
Quinazolinone Derivatives as Anti-HIV-1 Agents.
Curr. HIV Res. (2019) 17: 214-22.
HyperChem(TM) Professional 8.0, Hypercube, Inc.,
1115 NW 4th Street, Gainesville, Florida 32601, USA.
Morris GM, Goodsell DS, Halliday RS, Huey R, Hart
WE, Belew RK and Olson AJ. Automated Docking
Using a Lamarckian Genetic Algorithm and and
Empirical Binding Free Energy Function. J. Comput.
Chem. (1998) 19: 1639-62.
Trott O and Olson AJ. AutoDock Vina: improving the
speed and accuracy of docking with a new scoring
function, efficient optimization, and multithreading. J.
Comput. Chem. (2010) 31: 455-61.
Wakita T, Pietschmann T, Kato T, Date T, Miyamoto
M, Zhao Z, Murthy K, Habermann A, Kräusslich H-G
and Mizokami M. Production of infectious hepatitis C
virus in tissue culture from a cloned viral genome. Nat.
Med. (2005) 11: 791-6.
Gould Jr. R and Jacobs W. The synthesis of certain
substituted quinolines and 5,6-benzoquinolines. J. Am.
Chem. Soc. (1939) 61: 2890-5.
Blight KJ, Kolykhalov AA and Rice CM. Efficient
initiation of HCV RNA replication in cell culture.
Science (2000) 290: 1972-4.
Bressanelli S, Tomei L, Rey FA and De Francesco
R. Structural analysis of the hepatitis C virus RNA
polymerase in complex with ribonucleotides. J. Virol.
(2002) 76: 3482-92.
Deore RR, Chen GS, Chang PT, Chern TR, Lai SY,
Chuang MH, Lin JH, Kung FL, Chen CS, Chiou CT
and Chern JW. Discovery of N-arylalkyl-3-hydroxy-4-
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
(34)
(35)
(36)
(37)
(38)
(39)
(40)
(41)
 Mahboubi Rabbani SMI et al. / IJPR (2019), 18 (4): 1790-1802
1802
oxo-3,4-dihydroquinazolin-2-carboxamide derivatives
as HCV NS5B polymerase inhibitors. ChemMedChem
(2012) 7: 850-60.
Bhatt A, Gurukumar KR, Basu A, Patel MR,
Kaushik-Basu N and Talele TT. Synthesis and SAR
optimization of diketo acid pharmacophore for HCV
NS5B polymerase inhibition. Eur. J. Med. Chem.
(2011) 46: 5138-45.
Zhong D, Liu M, Cao Y, Zhu Y, Bian S, Zhou J, Wu F,
Ryu KC, Zhou L and Ye D. Discovery of Metal Ions
Chelator Quercetin Derivatives with Potent Anti-HCV
Activities. Molecules (2015) 20: 6978-99